NASDAQ:ARTL

Artelo Biosciences Stock News

Healthcare > Biotechnology

Buy ARTL

*Your capital is at risk

$0.770

+0.0148 (+1.96%)

At Close: Jul 31, 2026

Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023

08:30am, Thursday, 02'nd Nov 2023

SOLANA BEACH, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop tre

Principal Investigator of Artelo's CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia

08:30am, Wednesday, 04'th Oct 2023

SOLANA BEACH, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop tre

Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th

08:30am, Wednesday, 13'th Sep 2023

SOLANA BEACH, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop tr

Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12

08:00am, Thursday, 07'th Sep 2023

SOLANA BEACH, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop t

Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th

09:00am, Wednesday, 06'th Sep 2023

SOLANA BEACH, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop tr

Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th

09:00am, Tuesday, 05'th Sep 2023

SOLANA BEACH, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop trea

Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

08:00am, Thursday, 10'th Aug 2023

$14.0 Million in Cash and Investments as of June 30, 2023; Cash Runway Expected to Support Operations into the Second Half of 2024 $14.0 Million in Cash and Investments as of June 30, 2023; Cash Runwa

Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023

09:00am, Wednesday, 19'th Jul 2023

New data demonstrates that ART26.12 works by activating multiple receptors implicated in pain signaling and is able to broadly modify lipids in chemotherapy-induced peripheral neuropathy New data demo

Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium

08:30am, Wednesday, 07'th Jun 2023

ART12.11, a Novel and Patented Cocrystal of Cannabidiol, Improves Bioavailability and Efficacy of CBD ART12.11, a Novel and Patented Cocrystal of Cannabidiol, Improves Bioavailability and Efficacy o

Artelo Biosciences to Present at MicroCap Rodeo's Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 22, 2023

08:30am, Wednesday, 15'th Feb 2023

SOLANA BEACH, CA / ACCESSWIRE / February 15, 2023 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by